Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study

Luana M. S. Marins1,*, Thiago S. Torres1, Iuri da C. Leite2, Ronaldo I. Moreira1, Paula M. Luz1, Brenda Hoagland1, Esper G. Kallas3, José Valdez Madruga4, Albert Y. Liu5, Peter L. Anderson6, Beatriz Grinsztejn1, Valdilea G. Veloso1

1 Fundação Oswaldo Cruz, Instituto Nacional de Infectologia Evandro Chagas (INI/Fiocruz), Rio de Janeiro, Brazil, 2 Fundação Oswaldo Cruz, Escola Nacional de Saúde Pública (ENSP/Fiocruz), Rio de Janeiro, Brazil, 3 Universidade de São Paulo, Escola de Medicina, São Paulo, Brazil, 4 Centro de Referência e Treinamento em DST/AIDS, São Paulo, Brazil, 5 San Francisco Department of Public Health, Bridge HIV, San Francisco, California, United States of America, 6 Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, United States of America

* luana.marins@ini.fiocruz.br

Abstract

Introduction

Efficacy of daily emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for PrEP is strongly dependent on the adherence. We examined the concordance between indirect adherence measures and protective drug levels among participants retained through 48 weeks in the PrEP Brasil Study.

Methods

PrEP Brasil was a prospective, multicenter, open-label demonstration project evaluating PrEP provision for men who have sex with men (MSM) and transgender women (TGW) at higher risk for HIV infection within the setting of Brazilian Public Health System. Three indirect adherence measures were obtained at week 48: medication possession ratio (MPR), pill count and self-report (30-days recall). Tenofovir diphosphate (TFV-DP) concentration in Dried Blood Spot (DBS) was measured at week 48. Areas under (AUC) the receiver operating characteristics (ROC) curve were used to evaluate the concordance between achieving protective drug levels (TFV-DP ≥ 700 fmol/punch) and the indirect adherence measures. Youden’s index and distance to corner were used to determine the optimal cutoff points for each indirect adherence measure. We calculated sensitivity, specificity, negative (NPV) and positive (PPV) predictive values for the found cutoff points. Finally, Delong test was used to compare AUCs.

Results and discussion

From April, 2014 to July, 2016, 450 participants initiated PrEP, 375 (83.3%) were retained through 48 weeks. Of these, 74% (277/375) had TFV-DP ≥ 700 fmol/punch. All adherence
measures discriminated between participants with and without protective drug levels (AUC > 0.5). High indirect adherence measure was predictive of protective drug levels (PPV > 0.8) while low indirect adherence measure was not predictive of lack of protective drug levels (NPV < 0.5). No significant differences were found between the adherence methods (p = 0.44).

Conclusions

Low-burden measurements such as MPR and self-report can be used to predict PrEP adherence in a public health context in Brazil for MSM and TGW retained through 48 weeks.

Clinical Trial Number: NCT01989611.

Introduction

Pre-exposure prophylaxis (PrEP) refers to the use of antiretroviral medications (ARV) by HIV-negative individuals aiming to reduce their risk of HIV infection. It is one of the most promising strategies in the field of biomedical HIV prevention [1]. The efficacy and safety of oral tenofovir disoproxil fumarate plus emtricitabine (FTC/TDF) as PrEP has been demonstrated in several trials [2–7].

Cumulative evidence provided by iPrEX study [2], Partners PrEP [8] and TDF2 trial [6] led the United States Food and Drug Administration (FDA) to approve daily FTC/TDF for PrEP in July 2012 [9]. Now PrEP is available in numerous countries, including Brazil, where since December 2017, it has been offered as a public health policy to populations at high risk of acquiring HIV, as men who have sex with men (MSM) and transgender women (TGW) [10].

Brazil has been a pioneer in Latin America HIV/AIDS policies for both treatment and prevention [11], with universal free access to ARV and human rights-based prevention programs centered on behavioral and structural interventions [12]. Following the accumulated evidence on PrEP efficacy, since 2013 the Brazilian Ministry of Health (MoH) has supported projects on acceptability and feasibility of PrEP use in the country so as to generate evidence for the construction of the PrEP national policy [13]: PrEP Brasil [14]; Combina Project; PrEParadas Study; Horizon Project; Transgender Women Project Federal University of Bahia and ImPrEP [15]. PrEP demand was estimated to be 66,000–98,000 of Brazilian MSM aged 15–64 years [16] and from January to September 2018, 5,712 individuals initiated PrEP provided by the MoH [17].

Adherence is a critical component to PrEP effectiveness and high levels of PrEP use are essential to maximize the public health impact of this prevention strategy [18,19]. During PrEP Brasil study, the main barriers to PrEP adherence were forgetting doses, change in daily routine, pills shortage and not having pills available at the time of dose. The three main facilitators were associating PrEP with some daily activity, being engaged with PrEP and keeping the tablets in some visible place [20]. More recently, an online survey conducted among 11,367 Brazilian MSM found the main barriers to PrEP use to be related to information about PrEP such as fear of not being 100% protected against HIV, of side effects, and that ART would not work if infected. PrEP with no cost, access to free HIV test and access to personal PrEP counseling were the main facilitators of PrEP use [21].

A pharmacokinetic modeling study demonstrated the relationship between PrEP use and protective efficacy, showing that adherence is essential for maximizing the effectiveness of PrEP [3,22,23]]. However, accurate assessment of adherence is challenging. Existing methods
of assessing adherence are limited for various reasons that have been well described in the literature [23–27], and there is no gold standard for adherence measurement [24,28]. Drug concentration levels could be considered the most accurate measure to quantify adherence, but the high costs of available methodologies make it unfeasible for implementation in routine clinical practice, especially in a public health context [28].

In this study, we examined the concordance between three indirect adherence measures (medication possession ratio, pill count and self-report) and highly protective drug levels measured from dried blood spot (DBS) among participants retained through 48 weeks in the PrEP Brasil Study.

Methods

As described in detail previously [14,29], PrEP Brasil was a prospective, multicenter, open-label demonstration project evaluating PrEP provision for MSM and TGW at higher risk for HIV infection in the context of the Brazilian Public Health System. Study design and 48-weeks’ results on retention, engagement, ethics and adherence measured by drug levels were published elsewhere [14]. All procedures were conducted according to the principles expressed in the Declaration of Helsinki. The present analysis was approved by INI-Fiocruz Review Board (#08405912.9.1001.5262).

Participants received a bottle containing 30 pills of FTC/TDF at enrollment and, subsequently, were provided with a sufficient supply of pills for daily treatment until the next study visit (weeks 4, 12, 24, 36 and 48). Study pharmacists instructed the participants to take one tablet daily and advised them to return FTC/TDF pills in the original bottle to the pharmacy, whether used or not. At each study visit, the pharmacists provided adherence support and counseling. At week 48, we measured adherence using three different methods: (a) medication possession ratio (MPR); (b) pill count; and (c) self-report.

MPR reflects the days the participant is “covered” by the study medication. It is calculated by the ratio of the number of pills dispensed at the prior visit and the number of days between that visit and the week 48 visit. MPR values equal or greater than 1.00 indicate 100% coverage, and values below 1.00 reflect that the participant was not covered by the study medication during all the days between week 48 and the prior visit [30].

Pill count was calculated by the number of pills dispensed at the prior visit minus the number of pills returned at week 48, divided by the number of days between the two visits. Values are given in percentage. We could not calculate pill count for the participants who did not return any bottle of study medication for counting at week 48. These cases were considered missing data and not included in the accuracy analysis (n = 42).

Self-report was assessed using one question from a structured questionnaire (“On average for how many days did you forget to take FTC/TDF in the previous 30 days?”) administered by study pharmacists. Values are given in percentage. Participants attending the week 48 visit who refused to answer the questionnaire (n = 28) were considered missing and not included in the accuracy analysis.

DBS specimens were collected for tenofovir diphosphate (TFV-DP) assessments for all participants who attended the week 48 visit. TFV-DP levels were measured using liquid chromatography-mass spectrometry tandem mass spectrometry (LC-MS/MS) at the University of Colorado Antiviral Pharmacology Laboratory (Aurora, CO, USA) with standard procedures [3,31,32].

Results from iPrEX Open-label study demonstrated the following correspondence of doses taken per week, TFV-DP concentration and levels of protection: a TFV-DP concentration ≥700 fmol/punch, corresponding to ≥4 doses/week, was associated with a 100% (95% CI 86%
to 100%) reduction in HIV transmission risk; and a TFV-DP concentration of 350–699 fmol/punch, corresponding to 2–3 doses/week, was associated with a 86% (21% to 99%) reduction in HIV transmission risk [3]. For the purposes of this analysis, TFV-DP levels were dichotomized as highly protective drug levels (≥ 700 fmol/punch) vs. poorly protective drug levels (<700 fmol/punch) [33].

The area under the curve (AUC) was estimated using a receiver operating characteristics (ROC) curve analysis to evaluate the accuracy of each indirect adherence measure in discriminating between those with or without highly protective drug levels. From the ROC curve, the optimal cutoff points for discriminating between those with or without protective drug levels were found based on the Youden index and the distance to corner [34–36]. Sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) for the cutoff points were calculated. Statistical comparisons of the AUC for each adherence measure were performed with the DeLong test, a nonparametric method commonly used to identify differences among AUC [37]. This method does not assume the strong normality assumptions that the alternative Binormal method makes. Analyses were conducted using SAS version 9.4 (SAS Institute, North Carolina, USA).

Results

From April 2014 to July 2016, 450 participants initiated PrEP, of whom 375 (83%) were retained for 48 weeks. Table 1 depicts baseline characteristics for the 375 participants included compared with the 75 participants not included in this analysis. The full baseline characteristic for these participants are presented in previous work by the authors [14]. At week 48, 277 (74%) of the 375 participants had highly protective drug levels consistent with at least four

Table 1. Baseline characteristics of participants included in this analysis vs. not included.

|                          | Total | Included n (%) | Not included n (%) | p-value |
|--------------------------|-------|----------------|--------------------|---------|
| Overall                  | 450   | 375 (83)       | 75 (17)            |         |
| Site Location            |       |                |                    |         |
| RJ                       | 180   | 150 (83)       | 30 (17)            | 1.00    |
| SP                       | 270   | 225 (83)       | 45 (17)            |         |
| Age                      |       |                |                    |         |
| 18–24 years              | 113   | 92 (81)        | 21 (19)            | 0.52    |
| 25–34 years              | 214   | 179 (84)       | 35 (16)            | 0.83    |
| ≥35 years                | 123   | 104 (85)       | 19 (15)            |         |
| Schooling                |       |                |                    |         |
| < 12 years               | 115   | 93 (81)        | 22 (19)            | 0.41    |
| ≥ 12 years               | 335   | 282 (84)       | 53 (16)            |         |
| Color/Race               |       |                |                    |         |
| White                    | 243   | 205 (84)       | 38 (16)            |         |
| Black                    | 57    | 47 (82)        | 10 (18)            | 0.72    |
| Mixed                    | 145   | 118 (81)       | 27 (19)            | 0.45    |
| Gender                   |       |                |                    |         |
| Male                     | 425   | 354 (83%)      | 71 (17%)           | 0.93    |
| Transwomen               | 25    | 21 (84%)       | 4 (16%)            |         |
| Steady partner           |       |                |                    |         |
| Yes                      | 233   | 194 (83%)      | 39 (17%)           | 0.87    |
| No                       | 204   | 171 (84%)      | 33 (16%)           |         |

https://doi.org/10.1371/journal.pone.0221281.t001
doses per week [14]. Median adherence rates were 1.10 (IQR 0.98–1.31) for MPR, 97.14% (IQR 88.89–100.00) for pill count and 100.00% (IQR 93.33–100.00) for self-report. Among 42 participants who did not return any bottle of FTC/TDF for pill count, 35.7% and 64.3% had high and low protective drug levels, respectively. As for the 28 participants who did not complete the self-report questionnaire, 28.6% and 71.4% had high and low protective drug levels, respectively.

According to the ROC curves, the three indirect adherence measures can predict highly protective drug levels at week 48 (Fig 1). The area under the ROC curve was 0.70 for MPR, 0.68 for pill count and 0.65 for self-report.

The cutoff value associated with highly protective levels of TFV-DP according to the highest Youden index was 1.07 for MPR, 90.09% for pill count and 99.90% for self-report (Table 2). The proportion of participants with adherence values equal to or higher than the cutoff point was as follows: 62.9% for MPR (236/375); 72.4% for pill count (241/333); and 59.6% for self-report (207/347).

The concordance between the adherence methods, in terms of positive predictive values (PPV) and negative predictive values (NPV), is depicted in Table 2. For all indirect adherence measures, high indirect adherence measures were predictive of protective drug levels (PPV>0.8), while low recorded adherence was not predictive of a lack of protective drug levels (NPV<0.5).

Comparison using the DeLong test showed no significant differences between the three indirect adherence measures in the ability to discriminate participants with and without protective drug levels (p = 0.44).

Table 2. Association between indirect adherence measures and protective drug levels.

| Adherence measures | AUC (95% CI) | P-value | Cutoff point | Sensitivity | Specificity | PPV    | NPV    |
|-------------------|-------------|---------|--------------|-------------|------------|--------|--------|
| MPR               | 0.70(0.63–0.76) | <0.001  | 1.07         | 0.68        | 0.62       | 0.84   | 0.41   |
| Pill count        | 0.68(0.60–0.76) | <0.001  | 90.09        | 0.77        | 0.62       | 0.86   | 0.47   |
| Self-report       | 0.65(0.58–0.72) | <0.001  | 99.90        | 0.64        | 0.56       | 0.84   | 0.31   |

MPR = medication possession ratio; PPV = positive predictive value; NPV = negative predictive value.
Discussion

The main purpose of this study was to assess the concordance between a pharmacologic measure of exposure and “traditional”, feasible and low-cost adherence measures (pill count, medication possession ratio and self-report). This is the first study to evaluate the correlation of indirect adherence measurements in the context of a public health program in a middle-income country. As previously mentioned, PrEP efficacy is strongly dependent on adherence, thus, the identification of whether an individual in a PrEP Program is adherent or not is of great importance in the clinical setting. Each adherence measure has its strengths and weaknesses [26,27].

We observed high levels of adherence among participants retained through 48 weeks in PrEP Brasil study using all indirect adherence measurements (MPR, pill count and self-report) as well as by TFV-DP levels [14]. High adherence levels based on drug levels diverge from previous placebo-controlled PrEP trials [2,28,38,39], but such levels are consistent with findings from recent open-label and demonstration projects [28,40–43]. This result was expected, as people feel more comfortable using PrEP once more safety and efficacy results become available, and when such results are obtained outside a placebo-controlled study [28,44]. We observed low levels of adherence based on drug levels for those who did not return their bottles for pill count and for those who chose not to answer the self-report measure. Although a great effort was made to perform these assessments in a neutral supportive environment without judgment or direct persuasion, we suppose, given their low levels of adherence, that these individuals wanted to avoid any discomfort or fear to report socially undesired behavior.

Our results showed that all indirect adherence measures could discriminate participants with and without protective drug levels with fair discriminatory ability (AUC>0.5) among participants retained through 48 weeks. Additionally, there were no differences between the three indirect adherence measures in the ability to discriminate between participants with and without protective drug levels. The efficacy of adherence measures in discriminating between achieving or not achieving protective drug levels vary among clinical trials, a finding that can be explained by the differences in the study location and demographic characteristics. The results from iPrEx placebo-controlled trial which included 510 participants in 6 countries (Brazil, Ecuador, Peru, South Africa, Thailand and US) showed that only MPR was able to discriminate, with relatively poor discriminatory ability [30]. The Partners PrEP ancillary adherence study among East African serodiscordant couples also found poor discriminatory ability for self-report (AUC 0.56 [95% CI, 0.47–0.61]) and pill count (AUC 0.58 [95% CI, 0.46–0.60]) [42]. Likewise, the ATN-123 found that self-report could not accurately capture true levels of medication adherence among young MSM in US [45]. Nonetheless, the TDF2 PrEP trial in Botswana found a modest correlation between TFV drug levels and self-reported adherence (phi-coefficient = 0.28), and a weaker relationship between drug levels and pill count adherence (phi-coefficient = 0.20) [46]. The iPrEx open-label extension also found concordance for self-report with PPV and NPV of 83% (95% CI, 81.3–84.3) and 82% (95% CI, 81.3–84.3), respectively [47]. We also determined the best cutoff points to discriminate high levels of adherence. Considering these cutoff values, PPV values for the three indirect adherence measurements were higher than 0.80. This means that approximately 80% of individuals with adherence higher than the cutoff values also have high adherence based on TFV-DP levels; thus, high recorded adherence was predictive of highly protective levels. Although all indirect adherence measures presented high PPV, it is important to emphasize that the possibility of “false positive” responses must be considered within clinical practice, once individuals presenting high indirect adherence measure may not achieve highly effective level of protection and thus be at risk of HIV. This could prevent the access of these individuals to adherence support (adherence counseling, for example). The use of 2 or more adherence measures may be useful.
to identify more efficiently low adherence in “real world”, as discussed in the “WHO consultation on PrEP adherence” [48]. Abaasa et al. [49] demonstrated the incremental value of combining adherence measures (electronic monitoring, self-report, and drug concentrations in plasma and hair). However, the authors used objective adherence measures, so more studies are needed on how the use of two or more indirect adherence measure can give an accurate picture of PrEP adherence.

Conversely, NPV values were low (<0.5), indicating that low recorded adherence was not predictive of a lack of protective drug levels. This finding can be explained by the fact that a highly protective drug level (≥700fmol/punch) can be achieved with less frequent dosing (4 pills/week) than the current approved recommendation of daily PrEP. Even those with low measured adherence may still have protective drug levels. It means that for achieving highly effective levels of protection (TFV-DP ≥ 700fmol/punch) the average adherence over the period must be approximately 57% (4 taken doses/7 days = 0.57). It is important to note that the best cutoff points estimated in our study (1.07; 90.09% and 99.90%, for MPR, pill count and self-report, respectively) are higher than 57%, thus it is plausible that an individual with adherence lower than a given cutoff point could still achieve levels of protection.

Self-report is the most common adherence measure in clinical practice [50]. The major strengths of this measure are ease of collection, low cost and the accuracy of reported non-adherence [26]. Conversely, it depends on the participants’ memory or comfort in providing truthful information [51], thus this measurement is subject to bias (recall and social desirability bias) which often lead to overestimation of adherence. A way to improve self-report adherence is providing an environment where the individual feels at ease and confident in reporting socially undesired behavior [26]. Pill count is a more objective adherence measure and more accurate when compared to self-report. This measure is also easy to collect and relatively inexpensive [26], though, as limitations, it is time consuming and subject to manipulation (for example, pills discarded, lost or shared with others) and might not reflect the pattern of PrEP use [27,52]. MPR is derived through dispensation records, it corresponds to the percentage of days during which individuals are in possession of their medications [53] reflecting the pill coverage during a given time. Similarly to pill count, MPR do not provide PrEP pattern use as it indicates pharmacy dispensation rather than drug ingestion. MPR above 1.0, for example, does not necessary mean over adherence, but indicates that an individual possesses enough medication to cover a given time of PrEP use. According to “WHO consultation on PrEP adherence”, pharmacy refill “may be interpreted as maximal predicted PrEP adherence” [48]. MPR may be a powerful tool for adherence assessment, especially if dispensation information is accurate and accessible. The Brazilian experience with SICLOM (the National Computerized System for the Control of Drug Logistics)—which contains specific information about antiretroviral dispensation, including PrEP—suggests that this type of database could provide a unique data source for adherence assessment in the country and perhaps elsewhere [54].

The present study has some limitations. First, the different time periods associated with each indirect adherence measure assessment (30-day recall for self-report, 90-day recall for pill count and MPR) and TFV-DP assessment (a 17-day half-life corresponding to cumulative adherence over 1–3 months) may impact comparisons. It is a common limitation when comparing a pharmacokinetic measure with a non-pharmacokinetic measure [30,42,49]. TFV-DF levels in DBS has a long half-life of 17 days, which provides an average adherence of 1 to 3 months [31,48], as red blood cells live in blood circulation for 100 to 120 days [55]. However, neither TFV-DF levels nor indirect adherence measures (MPR, pill counts and self-report) can provide patterns of FTC/TDF scheduling use over the mentioned period. Despite the different periods of assessment, the rationale for this analysis was to seek evidence on whether the three indirect adherence measures could or not discriminate participants that achieved highly-
effective level of protection by using at least an average of 4 doses/week of PrEP, independently of the FTC/TDF scheduling use. Furthermore, it is already well established that through the determination of drug levels of TFV-DF in DBS we are able to assess the adherence “categories” of a given individual (7 doses/week; ≥ 4–7 doses/week; 2–3 doses/week and <2 doses/week). These categories have been used in PrEP demonstration projects to estimate gradients of adherence [56]. Second, TFV-DP levels were dichotomized as highly protective drug levels or poorly protective drug levels, limiting the interpretation of correlation data from this analysis. Third, drug levels were assessed for participants attending the week 48 visit, thus we assessed the performance of indirect adherence measures only for these participants. Though this limitation could have led to selection bias, we argue that, if any, the impact was minimal. We have previously reported that there was no significant difference on baseline characteristics between participants retained and not retained at week 48. Importantly, there was no difference in the levels of TFV-DP measured at week 4 [29]. Fourth, the concordance between the indirect adherence measures was only obtained for the best cutoff points according to the aim of this study. For our analysis, we chose to give equal weight to sensitivity and specificity. Youden’s index and distance to corner were then used, and each sensitivity and specificity combination in the output was considered. Lastly, the low levels of adherence based on drug levels for those considered missing for pill count and self-report may have led to an overestimation in the discriminatory ability of these indirect adherence measures.

Conclusions

In conclusion, this study provided the opportunity to assess the concordance between drug exposure and other indirect adherence measures in a real-world public health PrEP program. Our results highlight the utility of low-burden measurements such as MPR and self-report in predicting adherence among our target population. These measurements can be useful in monitoring PrEP use among MSM and TGW retained in a PrEP program and in guiding the need for adherence interventions. Studies on incremental value of combining MPR and self-report in predicting adherence among our target population are needed.

Acknowledgments

The authors would like to thank the following: the study participants; the PrEP Brasil Study Team; and the University of Colorado Antiviral Pharmacology Laboratory. The authors also acknowledge the support of our funders: CNPq; Secretaria de Vigilancia Sanitaria; FAPERJ; FAPESP; and Gilead Sciences.

Part of this study was presented as an Oral Abstract during the International AIDS Conference, Amsterdam, July 24th, 2018 [57].

Author Contributions

Conceptualization: Beatriz Grinsztejn, Valdilea G. Veloso.

Data curation: Luana M. S. Marins, Thiago S. Torres.

Formal analysis: Thiago S. Torres, Iuri da C. Leite, Ronaldo I. Moreira.

Funding acquisition: Beatriz Grinsztejn, Valdilea G. Veloso.

Investigation: Luana M. S. Marins, Thiago S. Torres, Brenda Hoagland, Esper G. Kallas, José Valdez Madruga, Beatriz Grinsztejn, Valdilea G. Veloso.

Methodology: Luana M. S. Marins, Thiago S. Torres, Beatriz Grinsztejn, Valdilea G. Veloso.
Project administration: Beatriz Grinsztejn.

Resources: Beatriz Grinsztejn, Valdilea G. Veloso.

Software: Iuri da C. Leite, Ronaldo I. Moreira.

Visualization: Thiago S. Torres, Iuri da C. Leite, Ronaldo I. Moreira.

Writing – original draft: Luana M. S. Marins, Thiago S. Torres, Beatriz Grinsztejn, Valdilea G. Veloso.

Writing – review & editing: Thiago S. Torres, Iuri da C. Leite, Ronaldo I. Moreira, Paula M. Luz, Brenda Hoagland, Esper G. Kallas, José Valdez Madruga, Albert Y. Liu, Peter L. Anderson.

References

1. Spinner CD, Boesecke C, Zink A, Jessen H, Stellbrink H-J, Rockstroh JK, et al. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2016 Apr; 44(2):151–8. https://doi.org/10.1007/s15010-015-0850-2 PMID: 26471511

2. Grant RM, Lamia JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New England Journal of Medicine. 2010 Dec 30; 363(27):2587–99. https://doi.org/10.1056/NEJMoa1011205 PMID: 21091279

3. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. The Lancet Infectious Diseases. 2014 Sep; 14(9):820–9. https://doi.org/10.1016/S1473-3099(14)70847-3 PMID: 25065957

4. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. The Lancet. 2016 Jan; 387(10013):53–60.

5. Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charrasse I, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. New England Journal of Medicine. 2015 Dec 3; 373(23):2237–46. https://doi.org/10.1056/NEJMoa1506273 PMID: 26624850

6. Thigpen MC, Keabaetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral Pre-exposure Prophylaxis for Heterosexual HIV Transmission in Botswana. New England Journal of Medicine. 2012 Aug 2; 367(5):423–34. https://doi.org/10.1056/NEJMoa1110711 PMID: 22784038

7. Pojaros C, Haberer JE, Katabira E, Ronald A, Tumwesiye E, Campbell JD, et al. An Intervention to Support HIV Preexposure Prophylaxis Adherence in HIV-Serodiscordant Couples in Uganda: JAIDS Journal of Acquired Immune Deficiency Syndromes. 2014 Aug; 66(5):522–9. https://doi.org/10.1097/QAI.0000000000000212 PMID: 24853311

8. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. New England Journal of Medicine. 2012 Aug 2; 367(5):399–410. https://doi.org/10.1056/NEJMoa1108524 PMID: 22784037

9. FDA. Truvada for PrEP Fact Sheet: Ensuring Safe and Proper Use [Internet]. 2012 [cited 2018 Oct 26]. https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM312290.pdf

10. WHO. Brazil begins PrEP roll-out on World AIDS Day [Internet]. World Health Organization. 2017 [cited 2018 Oct 29]. http://www.who.int/hiv/mediacentre/news/brazil-prep/en/

11. Galea JT, Baruch R, Brown B. ¡PrEP Ya! Latin America wants PrEP, and Brazil leads the way. The Lancet HIV. 2018 Mar; 5(3):e110–2. https://doi.org/10.1016/S2352-3018(18)30011-0 PMID: 29467099

12. Grangeiro A, Couto MT, Peres MF, Luiz O, Zucchi EM, de Castilho EA, et al. Pre-exposure and post-exposure prophylaxes and the combination HIV prevention methods (The Combinet! Study): protocol for a pragmatic clinical trial at public healthcare clinics in Brazil. BMJ Open. 2015 Aug; 5(8):e009021. https://doi.org/10.1136/bmjopen-2015-009021 PMID: 26307622

13. Ministério da Saúde publica protocolo para utilização da PrEP [Internet]. [cited 2019 May 18]. http://portais.saude.gov.br/noticias/agencia-saude/26553-ministerio-da-saude-publica-protocolo-para-utilizacao-da-prep

14. Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, et al. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in...
PrEP—O ESTADO DE IMPLANTAÇÃO

Hoagland B, Moreira RI, De Boni RB, Kallas EG, Madruga JV, Vasconcelos R, et al. High pre-exposure

Haberer JE. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine

Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ, et al. High Interest in Pre-

Baxi SM, Liu A, Bacchetti P, Mutua G, Sanders EJ, Kibengo FM, et al. Comparing the Novel Method of

Luz PM, Benzaken A, de Alencar TM, Pimenta C, Veloso VG, Grinsztejn B. PrEP adopted by the brazil-

Amico KR, Marcus JL, McMahan V, Liu A, Koester KA, Goicochea P, et al. Study Product Adherence

PAHO/WHO | Brazil initiated the implementation of PrEP to prevent new cases of HIV among key

Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures: JAIDS Journal of Acquired Immune Deficiency Syndromes. 2015 Jan; 68(1):13–20. https://doi.org/10.1097/QAI.0000000000000386 PMID: 25296098

Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ, et al. High Interest in Pre-

T.S. Torres, L.M.S. Marins, P.M. Luz, R.I. Moreira, I.D. Costa Leite, B. Hoagland, et al. Predictors of

Seifert SM, Glidden DV, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, et al. Dose

Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-Tenofovir

2018 May; 97:S75–7. https://doi.org/10.1097/MD.00000000000010602 PMID: 29794605

PrEP—O ESTADO DE IMPLEMENTAÇÃO DA PREP NO BRASIL | Boletim Vacinas Anti-HIV/AIDS n°32—Fevereiro de 2019—| GIV—Grupo de Incentivo à Vida | [Internet]. [cited 2019 May 18]. http://giv.org.br/boletimvacinas/32/08-prep-implementacao-no-brasil.php

Hoagland B, Moreira RI, De Boni RB, Kallas EG, Grinsztejn B. PrEP adopted by the brazilian national health system: What is the size of the demand? Medicine. 2018 May; 97:S75–7. https://doi.org/10.1097/MD.00000000000010602 PMID: 29794605

PrEP Brasil: 48 week results of a demonstration study. The Lancet HIV. 2018 Mar; 5(3):e136–45. https://doi.org/10.1016/S2352-3018(18)30008-0 PMID: 29467098

15. PAHO/WHO | Brazil initiated the implementation of PrEP to prevent new cases of HIV among key

16. Luz PM, Benzaken A, de Alencar TM, Pimenta C, Veloso VG, Grinsztejn B. PrEP adopted by the brazilian national health system: What is the size of the demand? Medicine. 2018 May; 97:S75–7. https://doi.org/10.1097/MD.00000000000010602 PMID: 29794605

17. PrEP—O ESTADO DE IMPLEMENTAÇÃO DA PREP NO BRASIL | Boletim Vacinas Anti-HIV/AIDS n°32—Fevereiro de 2019—| GIV—Grupo de Incentivo à Vida | [Internet]. [cited 2019 May 18]. http://giv.org.br/boletimvacinas/32/08-prep-implementacao-no-brasil.php

18. Baxi SM, Liu A, Bacchetti P, Mutua G, Sanders EJ, Kibengo FM, et al. Comparing the Novel Method of

19. Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ, et al. High Interest in Pre-

20. T.S. Torres, L.M.S. Marins, P.M. Luz, R.I. Moreira, I.D. Costa Leite, B. Hoagland, et al. Predictors of

21. Torres TS, Konda K, Vega-Ramirez EH, Elorreaga Reyes OA, Diaz-Sosa D, Hoagland B, et al. Awareness

22. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-Tenofovir

23. Liu AY, Yang Q, Huang Y, Bacchetti P, Anderson PL, Jin C, et al. Strong Relationship between Oral

24. Williams AB, Amico KR, Bova C, Womack JA. A Proposal for Quality Standards for Measuring Medication Adherence in Research. AIDS and Behavior. 2013 Jan; 17(1):284–97. https://doi.org/10.1007/s10461-012-0172-7 PMID: 22407465

25. Seifert SM, Glidden DV, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, et al. Dose

26. Haberer JE, Bangsberg DR, Baeten JM, Curran K, Koechlin F, Amico KR, et al. Defining success with

27. Berg KM, Amsten JH. Practical and Conceptual Challenges in Measuring Antiretroviral Adherence: JAIDS Journal of Acquired Immune Deficiency Syndromes. 2006 Dec; 63(Supplement 1):S79–87. https://doi.org/10.1097/QAD.00000000000647 PMID: 25501614

28. Williams AB, Amico KR, Bova C, Womack JA. A Proposal for Quality Standards for Measuring Medication Adherence in Research. AIDS and Behavior. 2013 Jan; 17(1):284–97. https://doi.org/10.1007/s10461-012-0172-7 PMID: 22407465

29. Haberer JE, Bangsberg DR, Baeten JM, Curran K, Koechlin F, Amico KR, et al. Defining success with

30. Amico KR, Marcus JL, McMahan V, Liu A, Koester KA, Goicochea P, et al. Study Product Adherence Measurement in the iPrEx Placebo-Controlled Trial: Concordance With Drug Detection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2014 Aug; 66(5):530–7. https://doi.org/10.1097/QAI.000000000000216 PMID: 24853306
31. Castillo-Mancilla JR, Zheng J-H, Rower JE, Meditz A, Gardner EM, Predhomme J, et al. Tenofovir, Emtricitabine, and Tenofovir Diphosphate in Dried Blood Spots for Determining Recent and Cumulative Drug Exposure. AIDS Research and Human Retroviruses. 2012 Oct 10;121010062750004.

32. Zheng J-H, Rower C, McAllister K, Castillo-Mancilla J, Klein B, Meditz A, et al. Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. Journal of Pharmaceutical and Biomedical Analysis. 2016 Apr; 122:16–20. https://doi.org/10.1016/j.jpba.2016.01.038 PMID: 26829517

33. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. The Lancet Infectious Diseases. 2014 Sep; 14(9):820–9. https://doi.org/10.1016/S1473-3099(14)70847-3 PMID: 25063857

34. Najib-Tilaki K. The choice of methods in determining the optimal cut-off value for quantitative diagnostic test evaluation. Stat Methods Med Res. 2018 Aug; 27(8):2374–83. https://doi.org/10.1177/0962280216680383 PMID: 28673124

35. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its Associated Cut-off Point. Biom J. 2005 Aug; 47(4):458–72. PMID: 16161804

36. Najib-Tilaki K. Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation. Caspian J Intern Med. 2013; 4(2):627–35. PMID: 24099950

37. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach. Biometrics. 1988 Sep; 44(3):837. PMID: 3203132

38. Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, et al. FEM-PrEP: Adherence Patterns and Associated Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Pre-exposure Prophylaxis, Sexual Practices, and HIV Infection among African Women. New England Journal of Medicine. 2012 Aug 2; 367(5):411–22. https://doi.org/10.1056/NEJMoa1202614 PMID: 22784040

39. Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Dobblecki-Lewis S, Bacon O, et al. Pre-exposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. JAMA Internal Medicine. 2016 Jan 1; 176(1):75. https://doi.org/10.1001/jama.2015.4683 PMID: 26571482

40. Montgomery MC, Oldenburg CE, Nunn AS, Mena L, Anderson P, Liegler T, et al. Adherence to Pre-exposure Prophylaxis for HIV Prevention in a Clinical Setting. Datta PK, editor. PLOS ONE. 2016 Jun 22; 11(6):e0157742. https://doi.org/10.1371/journal.pone.0157742 PMID: 27333000

41. Musunuzi N, Muganzi CD, Boum Y, Ronald A, Marzinke MA, Hendrix CW, et al. Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa: AIDS. 2016 Apr; 30(7):1121–9. https://doi.org/10.1097/QAD.0000000000001024 PMID: 26785125

42. Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, et al. Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa. The Lancet Infectious Diseases. 2014 Sep; 14(9):820–9. https://doi.org/10.1016/S1473-3099(14)70847-3 PMID: 25063857

43. Baker Z, Javanbakht M, Mierzwa S, Pavel C, Lally M, Zimet G, et al. Predictors of Over-Reporting HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Young Men Who Have Sex With Men (YMSM in Self-Reported Versus Biomarker Data. AIDS and Behavior. 2018 Apr; 22(4):1174–83. https://doi.org/10.1007/s10461-017-1958-4 PMID: 29079950

44. Kebabetswe PM, Stirrat MJ, McLellan-Lemal E, Henderson FL, Gray SC, Rose CE, et al. Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitabine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007–2010. AIDS and Behavior. 2015 May; 19(5):758–69. https://doi.org/10.1007/s10461-014-0891-z PMID: 25186785

45. Amico KR, Mehrotra M, Avelino-Silva VI, McMahan V, For the iPrEx Study Team, Veloso VG, et al. Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study. AIDS and Behavior. 2016 Jul; 20(7):1535–40. https://doi.org/10.1007/s10461-016-1360-7 PMID: 26992393

46. World Health Organization. Consultation on pre-exposure prophylaxis (PrEP) adherence: meeting report. World Health Organization; 2014.
49. Abaasa A, Hendrix C, Gandhi M, Anderson P, Kamali A, Kibengo F, et al. Utility of Different Adherence Measures for PrEP: Patterns and Incremental Value. AIDS and Behavior. 2018 Apr; 22(4):1165–73. https://doi.org/10.1007/s10461-017-1951-y PMID: 29090394

50. Amico KR. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. Current Opinion in HIV and AIDS. 2012 Nov; 7(6):542–8. https://doi.org/10.1097/COH.0b013e3283582dd4 PMID: 22964887

51. Agot K, Taylor D, Corneli AL, Wang M, Ambia J, Kashuba ADM, et al. Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. AIDS and Behavior. 2015 May; 19(5):743–51. https://doi.org/10.1007/s10461-014-0859-z PMID: 25100053

52. Castillo-Man cilla JR, Haberer JE. Adherence Measurements in HIV: New Advancements in Pharmacologic Methods and Real-Time Monitoring. Current HIV/AIDS Reports [Internet]. 2018 Jan 29 [cited 2018 Apr 10]; http://link.springer.com/10.1007/s11904-018-0377-0

53. Kabore L, Muntner P, Chamot E, Zinski A, Burkholder G, Mugavero MJ. Self-Report Measures in the Assessment of Antiretroviral Medication Adherence: Comparison with Medication Possession Ratio and HIV Viral Load. Journal of the International Association of Providers of AIDS Care (JIAPAC). 2015 Mar; 14(2):156–62.

54. Sistema de Controle Logı ´ stico de Medicamentos (SICLOM) [Internet]. Departamento de Vigilância, Prevenção e Controle das IST, HIV/Aids e Hepatites Virais. [cited 2018 Dec 5]. http://www.aids.gov.br/pt-br/gestores/sistemas-de-informacao/sistema-de-controle-logistico-de-medicamentos-siclam

55. D’Alessandro A, Liumbruno GM, Grazzini G, Zolla L. Red blood cell storage: the story so far. Blood Transfusion [Internet]. 2010 [cited 2019 May 29]; http://doi.org/10.2450/2009.0122-09

56. Anderson PL, Liu AY, Castillo-Man cilla JR, Gardner EM, Seifert SM, McHugh C, et al. Intracellular Tenofovir-Diphosph ate and Emtricitab ine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Antimicrobial Agents and Chemotherapy [Internet]. 2017 Oct 16 [cited 2018 Oct 26]; 62(1). Available from: http://aac.asm.orglookup doi/10.1128/AAC.01710-17

57. Oral abstracts of the 22nd International AIDS Conference, 23–27 July 2018, Amsterdam, the Netherlands. Journal of the International AIDS Society. 2018 Jul; 21:e25148. https://doi.org/10.1002/jia2.25148 PMID: 30051631